Trial reportTransactions of the American Clinical and Climatological Association2014
Translational studies in older men using testosterone to treat sarcopenia.
Trial report in Transactions of the American Clinical and Climatological Association, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Effects of testosterone on lean mass gain in elderly men: systematic review with meta-analysis of controlled and randomized studies.Age (Dordrecht, Netherlands) · 2015Pooled it
- Bioelectrical impedance phase angle is associated with physical performance before but not after simulated multi-stressor military operations.Physiological reports · 2023Trial
- Efficacy of Testosterone plus NASA Exercise Countermeasures during Head-Down Bed Rest.Medicine and science in sports and exercise · 2018Trial
- A randomized trial of adjunct testosterone for cancer-related muscle loss in men and women.Journal of cachexia, sarcopenia and muscle · 2018Trial
- Strategies to mitigate muscle mass loss in individuals with spinal cord injury.The journal of spinal cord medicine · 2026Review
- Review
- Sarcopenia in the Aging Process: Pathophysiological Mechanisms, Clinical Implications, and Emerging Therapeutic Approaches.International journal of molecular sciences · 2025Review
- Sarcopenia and metabolic dysfunction associated steatotic liver disease: Time to address both.World journal of hepatology · 2024Article
- A review of the role of testosterone in the care of the critically ill patient.The Southern African journal of critical care : the official journal of the Critical Care Society · 2024Review
- Gastric Cancer with Sarcopenia: an Area Worth Focusing On.Current treatment options in oncology · 2023Review
- Protracted CLN3 Batten disease in mice that genetically model an exon-skipping therapeutic approach.Molecular therapy. Nucleic acids · 2023Article
- Article
- Lean nonalcoholic fatty liver disease and sarcopenia.Frontiers in endocrinology · 2023Review
- Cortisol enhances citrulline synthesis from proline in enterocytes of suckling piglets.Amino acids · 2021Article
- Dieckol Attenuated Glucocorticoid-Induced Muscle Atrophy by Decreasing NLRP3 Inflammasome and Pyroptosis.International journal of molecular sciences · 2021Article
- Combined Effects of Exercise and Phytoanabolic Extracts in Castrated Male and Female Mice.Nutrients · 2021Article
- Testosterone supplementation upregulates androgen receptor expression and translational capacity during severe energy deficit.American journal of physiology. Endocrinology and metabolism · 2020Article
- Exercise and Testosterone Countermeasures to Mitigate Metabolic Changes during Bed Rest.Life sciences in space research · 2020Article
- Testosterone Replacement Therapy and Rehospitalization in Older Men With Testosterone Deficiency in a Postacute Care Setting.American journal of physical medicine & rehabilitation · 2019Article
- Sarcopenia.Wiener medizinische Wochenschrift (1946) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Sarcopenia is the loss of skeletal muscle mass and strength that occurs with aging. Our research group has found an efficacious administration paradigm using testosterone to combat sarcopenia in humans. In addition, our research has uncovered an important regulatory enzyme of inflammation, nuclear factor-κB-inducing kinase that may regulate human skeletal muscle catabolism, and that appears to be counter-regulated by administration of standard doses of testosterone. This is important because a number of age-related clinical circumstances trigger acute and chronic muscle loss including cancer, chronic obstructive pulmonary disease, hospitalization, acute and chronic illness, and diseases in which systemic inflammation occurs. Moreover, it is often the treatment itself that can induce muscle loss. For example, glucocorticoids are tremendously effective at reducing inflammation and are a frontline therapy for many inflammatory-based diseases, yet paradoxically trigger muscle loss. We will discuss our research findings and the clinical significance of our human clinical translational research with testosterone.
Indexed as
Identifiers
25125716PMC4112698W49129270What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.